ASX Announcement

28 January 2026

TRIPP-FFX Trial Completes Last Patient, Last Visit (LPLV)

Sydney, Australia – 28 January 2026: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that Last Patient, Last Visit (LPLV) has been successfully completed in the TRIPP-FFX clinical trial.[1]

The TRIPP-FFX study is a prospective, multi-centre clinical trial evaluating the safety and efficacy of the OncoSil™ device when used in addition to FOLFIRINOX chemotherapy in patients with LAPC. TRIPP-FFX is a non-comparative, randomised design, with primary endpoints focused on Safety and Tolerability, and Local Disease Control Rate (LDCR) at 16 weeks. Secondary endpoints include Local Progression-Free Survival (LPFS), Progression-Free Survival (PFS), Overall Survival (OS), and other efficacy measures.

OncoSil completed patient recruitment for the trial in July 2025 (refer ASX announcement dated 23 July 2025). The Company has now successfully completed LPLV marking the completion of all patient treatments and follow-up assessments. The Company recruited a total of 88 patients into the trial across 15 sites in Europe and Australia.

With LPLV achieved, OncoSil will now proceed to final data cleaning and database lock, followed by statistical analysis in accordance with the trial protocol. The Company expects to present the trial results in the first half of calendar year 2026 (1H CY26), with a regulatory submission planned for the second half of calendar year 2026 (2H CY26) to extend the Company's current CE Mark by adding FOLFIRINOX as an additional chemotherapy option.

The TRIPP-FFX study has been designed to evaluate the use of the OncoSil™ device in addition to FOLFIRINOX, a widely adopted standard-of-care chemotherapy regimen in Europe for patients with LAPC. An extension of the product label, if successful, would allow physicians to use the OncoSil™ device in addition to FOLFIRINOX within the approved indication. The extension of the product label is subject to regulatory review and approval by the regulatory body (the British Standards Institute) based on a change notification to be submitted by OncoSil. If approved, this would provide clinicians with greater flexibility to integrate the OncoSil™ device into established treatment pathways, reflecting real-world clinical practice and addressing an area of high unmet medical need.

With the completion of the PANCOSIL Investigator-Initiated Study and the TRIPP-FFX trial, the Company will have concluded a major phase of its clinical trial investment in unresectable LAPC. These studies represent a significant body of clinical evidence generated to support the use of the OncoSil™ device in LAPC, and positions the Company to focus on regulatory engagement, label expansion opportunities, and broader commercial

[1] The trial will continue for long-term OS data collection

execution, subject to regulatory approvals.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"Achieving Last Patient, Last Visit in the TRIPP-FFX study represents an important operational milestone for the Company. The trial has been designed to generate clinical data evaluating the use of OncoSil™ in addition to FOLFIRINOX, which is intended to support future regulatory extensions of the product label. We thank the investigators, clinical teams, and patients for their contribution and now look forward to progressing through database lock and data analysis in accordance with the trial protocol."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	**Mr. Tim Luscombe & Mr. David Wood** Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	**Ms. Julia Maguire** **The Capital Network** Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Turkey, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en